Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Follow Brielle on Twitter @Brielle_Benyon.
Novel Drug Granted Priority Review for Acute Myeloid Leukemia Treatment
June 27th 2018The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.
Read More
Small Percentage With Myelofibrosis Develop Aggressive Lymphoma from JAK Inhibition
June 25th 2018While JAK inhibitors have proven to be an effective treatment for patients with myelofibrosis, a type of myeloproliferative neoplasm (MPN), they may come with a severe downside – in particular, a 16-fold increase in the chance of developing a B-cell lymphoma, according to recent research published in the journal Blood.
Read More
First Roundup Case Goes to Court, But the Jury Is Still Out on Whether it Causes Cancer
June 19th 2018Dewayne Johnson is the first of hundreds of patients to take Monsanto to trial, claiming that Roundup caused them to get cancer. His case will be seen even sooner than others because in California dying plaintiffs can be given expedited trials.
Read More
FDA Approves Avastin Regimen for Ovarian Cancer Treatment
June 13th 2018The Food and Drug Administration approved a combination of Avastin (bevacizumab) plus the chemotherapy agents carboplatin and paclitaxel, followed by Avastin alone, for the treatment of patients with advanced ovarian cancer who have had surgical resection.
Read More
FDA Approves Addition of Survival Data to Kyprolis Label for Multiple Myeloma Treatment
June 12th 2018The Food and Drug Administration (FDA) approved the supplemental New Drug Application to add to the U.S. Prescribing Information for Kyprolis (carfilzomib) for the treatment of patients with relapsed or refractory multiple myeloma.
Read More
Genetic Testing: The 'Train That Keeps On Chugging'
June 5th 2018Although genetic testing could be crucial in developing treatment plans and improving outcomes in women with ovarian and breast cancer, less than 20 percent of eligible patients actually get tested, according to Mike Janicek, M.D.
Read More
Broader Genetic Testing Can Save Costs, Determine Treatment Plans in Lung Cancer
June 1st 2018Using next-generation sequencing (NGS) to test patients with non-small cell lung cancer (NSCLC) for all known genetic mutations associated with the disease appeared to be faster and more cost-effective than testing for one gene at a time – not to mention the results could have treatment implications.
Read More
Half of Five-Year Survivors of Breast Cancer Are Not Receiving Recommended Post-Surgery Mammograms
May 25th 2018NCCN guidelines recommend annual mammograms to detect disease recurrence, but according to the study’s findings, women — even those who had adequate health insurance — were less likely to have their once-a-year mammogram as they became long-term survivors.
Read More
Patients and Caregivers Are on the 'Frontline' of Melanoma Monitoring
May 22nd 2018Recent research, conducted at NYU Langone Health and presented at the Oncology Nursing Society (ONS) Annual Congress, sought to find out how patients with melanoma perceived skin health education, and their willingness be involved in their own surveillance or a loved one’s.
Read More
Technology May Decrease Symptom Burden in Head and Neck Cancer Survivors
May 21st 2018Patients with head and neck cancer experienced a decrease in symptom severity after using mobile and sensor technology that allowed their health care providers to remotely monitor symptoms, according to research that will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
FDA Approves Combination for Rare Thyroid Cancer Type
May 4th 2018The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.
Read More
Immunotherapy in GU Cancers: Combinations Are the Next Step
May 4th 2018Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.
Read More